WASHINGTON – Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) today expressed support for the Food and Drug Administration Commissioner’s actions to help expand access to lower-cost prescription medications through improved transparency and reduced red tape.
“I’m encouraged by FDA Commissioner Gottlieb’s initiatives announced today. Competition in the prescription drug market is crucial to improving patient access to affordable medication. The FDA’s decision to publicly list off-patent drugs and expedite applications for lower-cost generics will help to foster greater drug competition for consumers. Just last week, I urged the FDA to examine legislation aimed at reducing anti-competitive behavior in the pharmaceutical industry and to work with the Justice Department and Federal Trade Commission to prevent abuses that delay generics from coming to market. So I look forward to further action by the FDA to increase access to less-costly prescription medicines,” Grassley said.
Grassley’s letter can be found HERE. Grassley is a sponsor of two bipartisan bills to end regulatory abuses by branded drug makers and pay-offs to generic drug makers that delay market access to less-costly alternatives.
